102-84-1

Basic information

• Product Name: Allyl phosphite
• Synonyms: allylphosphite;phosphorousacid,tri-2-propenylester;phosphorousacid,triallylester;TRIALLYL PHOSPHITE;triprop-2-enyl phosphite
• CAS NO: 102-84-1
• Molecular Formula: C₉H₁₅O₃P
• Molecular Weight: 202.19
• EINECS: 203-060-8
• Mol File: 102-84-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 84°C 12mm
• Flash Point: 84°C/12mm
• Appearance: Colorless/Liquid
• Density: 0.9983
• Vapor Pressure: 0.437mmHg at 25°C
• Solubility: Not miscible or difficult to mix.
• Sensitive: Air & Moisture Sensitive
• CAS DataBase Reference: Allyl phosphite(CAS DataBase Reference)
• NIST Chemistry Reference: Allyl phosphite(102-84-1)
• EPA Substance Registry System: Allyl phosphite(102-84-1)

Safety Data

• Statements: 20/21/22-36/37/38
• Safety Statements: 23-26-36/37/39
• RIDADR: UN3278
• RTECS: TH1772500
• TSCA: Yes
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 102-84-1(Hazardous Substances Data)

Usage

General Description

Allyl phosphite is a chemical compound with the molecular formula C3H7O3P, featuring an allyl group (C3H5) attached to a phosphite functional group (H2PO3). It can participate in a variety of chemical reactions, including polymerization and cross-linking processes, making it valuable in the production of specialty polymers and resins. Allyl phosphite's ability to introduce phosphorus-containing groups into organic molecules and polymers gives it a unique role in enhancing flame resistance and other desired properties in certain materials.

InChI:InChI=1/C9H15O3P/c1-4-7-10-13(11-8-5-2)12-9-6-3/h4-6H,1-3,7-9H2

Upstream product

• 101-02-0 triphenyl phosphite 
• 107-18-6 allyl alcohol 
• 15022-08-9 diallylcarbonate 

Downstream Products

• 1623-19-4 triallyl phosphate 
• 74038-34-9 diallyl benzylphosphonate 
• 221341-06-6 (S)-3-{2-[3-(4-{Amino-[(E)-tert-butoxycarbonylimino]-methyl}-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-(bis-allyloxy-phosphorylamino)-propionic acid methyl ester 
• 23679-20-1 diallyl phosphite 
• 107-05-1 3-chloroprop-1-ene 
• 556-56-9 allyl iodid 
• 3479-30-9 diallyl allylphosphonate 
• 98336-59-5 iodomethyl-phosphonic acid diallyl ester 
• 112057-45-1 {1-[1-(2,3-Dichloro-phenyl)-meth-(Z)-ylidene]-2-oxo-propyl}-phosphonic acid diallyl ester 
• 112057-43-9 {2-Oxo-1-[1-(3-trifluoromethyl-phenyl)-meth-(Z)-ylidene]-propyl}-phosphonic acid diallyl ester 
• 112057-46-2 {1-[1-(2-Difluoromethoxy-phenyl)-meth-(Z)-ylidene]-2-oxo-propyl}-phosphonic acid diallyl ester 
• 112057-29-1 5-(Bis-allyloxy-phosphoryl)-4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3-carboxylic acid methyl ester 
• 112057-21-3 Methyl 5-diallyloxyphosphinyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate 
• 112076-46-7 methyl 5-diallyloxyphosphinyl-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3-carboxylate 

Relevant articles and documents

-

-

Method for preparing unsaturated propyl phosphite ester and unsaturated propyl phosphate

The invention relates to a method for preparing unsaturated propyl phosphite ester or unsaturated propyl phosphate. The unsaturated propyl phosphite ester is selected from triallyl phosphite and tripropargyl phosphite, and the unsaturated propyl phosphate is selected from triallyl phosphate and tripropargyl phosphate. The method comprises the steps: enabling phosphorus trichloride or phosphorus oxychloride to react with allyl ester to form triallyl phosphite or triallyl phosphate; or enabling phosphorus trichloride or phosphorus oxychloride to react with propargyl ester to form propargyl phosphite or propargyl phosphate. The method for preparing unsaturated propyl phosphite ester or unsaturated propyl phosphate does not need any catalyst, and a by-product acyl chloride compound has a low boiling point and is easy to separate so that the unsaturated propyl phosphite ester or unsaturated propyl phosphate with high yield and high purity can be obtained.

The composite body deproteinizing chitosanoligosaccharide-

Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.